EVMN Q1 2025 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena

EVMNEvommune, Inc.

$319M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-57.1% YoY

Gross Profit

$3M87.4% margin

Operating Income

-$15M-501.1% margin

Net Income

-$15M-485.2% margin

EPS (Diluted)

$-0.48

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$56M

Total Liabilities

$214M

Stockholders' Equity

-$158M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$7M	-57.1%
Gross Profit	$3M	$7M	-61.0%
Operating Income	-$15M	-$4M	-300.4%
Net Income	-$15M	-$3M	-422.9%